Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 554
- Registration Number
- NCT04770896
- Locations
- 🇦🇹
Medizinische Universität Innsbruck; Universitätsklinik für Innere Medizin I, Innsbruck, Austria
🇦🇹Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria
🇦🇹Universitätsklinikum St. Pölten; Innere Medizin 2, St. Pölten, Austria
Abemaciclib With or Without Atezolizumab for mCRPC
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 75
- Registration Number
- NCT04751929
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo As a Treatment for Participants with Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT04740918
- Locations
- 🇺🇸
Emad Ibrahim, Md, Inc, Redlands, California, United States
🇦🇺Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
🇦🇺Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 31
- Registration Number
- NCT04739670
- Locations
- 🇦🇺
Royal North Shore, St Leonards, New South Wales, Australia
🇦🇺Mater Health, South Brisbane, Queensland, Australia
🇦🇺Monash Health, Melbourne, Victoria, Australia
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT04732286
- Locations
- 🇪🇸
Complejo Hospitalario Torrecardenas; Servicio de Hepatologia, Almeria, Spain
🇪🇸Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain
🇪🇸Hospital Universitario de Torrejon; Servicio de Oncología, Torrejón de Ardoz, Madrid, Spain
Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 54
- Registration Number
- NCT04730999
- Locations
- 🇮🇹
UOC Oncologia Medica 1 - AOU Careggi, Firenze, Italy
🇮🇹Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹Oncologia medica - Policlinico San Martino, Genova, Italy
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT04729959
- Locations
- 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Kaiser Permanente-Bellflower, Bellflower, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04721132
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 342
- Registration Number
- NCT04712643
- Locations
- 🇨🇳
Beijing You An Hospital; Digestive Dept, Beijing City, China
🇨🇳The 900th Hospital of PLA joint service support force, Fuzhou, China
🇨🇳Peking University First Hospital, Beijing City, China
Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 20
- Registration Number
- NCT04710498
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.